StayCurrentMD · Botulinum Toxin Enhanced Foker Process for Long Gap Esophageal Atresia
Article1 min read·Published Jul 2024Older

Botulinum Toxin Enhanced Foker Process for Long Gap Esophageal Atresia

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Jul 2024 · 1 min read

In brief

In brief

Novel surgical approach combines botulinum toxin A with the established Foker traction technique to treat long gap esophageal atresia in neonates. BTX's anti-fibrotic and muscle-relaxing properties may accelerate esophageal growth, potentially reducing operative stages and improving outcomes in this challenging congenital condition.

  • Foker process uses progressive tension to induce esophageal growth in long gap esophageal atresia (LGEA).
  • Botulinum Toxin A (BTX) has anti-fibrotic and muscle-relaxing properties relevant to esophageal tissue manipulation.
  • BTX may enhance traction-induced esophageal growth when combined with the Foker technique.
  • Novel approach targets both mechanical tension and tissue properties to improve LGEA surgical outcomes.

Written by the GCMD Library team from the article.

The traction-induced esophageal growth (Foker) process for the treatment of long gap esophageal atresia (LGEA) relies on applying progressive tension to the esophagus to induce growth. Due to its anti-fibrotic and muscle-relaxing properties, we hypothesize that Botulinum Toxin A (BTX) can enhance traction-induced esophageal growth.

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →